Clinical Trial Search

Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…

Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants

Primary: The Measurement of the Difference Between Early Morning and Evening Weights for CHF Patients — 2.47; 3.09 kilograms — p=<.001

Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants

Primary: Beck Depression Inventory II — 9.3; 9.2; 9.0; 8.6 units on a scale — p=0.90

Primary: Number of Participants With Treatment Related AEs and Serious Adverse Events (SAEs) — 0 Participants

Primary: Pre-dose Morning FEV1 at Week 8 - Change From Baseline — 0.021; 0.090; 0.070; -0.023 Litres — p=0.567

Primary: Body Weight (Amount of Change) — -0.45; -1.54 Kg — p=<0.0001

Primary: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure — 889; 828 Participants…

Primary: Number of Subjects With at Least 30 Days of Daily Impedance Measurements — 47; 106 participants

Primary: Short Physical Performance Battery (SPPB) at Month 3 — 6.9; 8.3 score on a scale — p=<0.0001

Primary: Bioelectrical Impedance Change — 47.52; 47.1; 41.27; 46.8 Percentage of Extra Cellular Fluid

Primary: Goal Attainment of Preventive Health Behaviors as Measured by the Goal Attainment Scale — 40; 40; 57.5; 52.5 t-score

Primary: the Safety Profile of CAP 1002; Any Subjects Experiencing Any Safety Related Events During or Post Intracoronary Delivery and During the Follow up Period. — 0; 1…

Primary: Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) — 193; 201; 171; 492 ng/mL

Primary: Re-hospitalization or Death — 48; 48 participants

Primary: Patient Quality of Life as Measured on the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score — 54.2; 51.1 score on a scale

Primary: (Randomized Arm) Composite Outcome of (1) HFHs, (2) Intravenous Diuretic Visits, and (3) All-cause Mortality — 0.563; 0.640 events per patient-year — p=0.1624

Primary: Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8 — -1.96; -1.74; -1.4; -1.84 kg

Primary: Adherence to Medication — 2; 3 Participants

Primary: Change From Baseline in FEV1 AUC(0-12h) Normalized by Time at Week 6 — 0.070; 0.118; 0.153; 0.147 Litres — p=0.037

Primary: Enrollment Rate — 39 Participants

Primary: 6 Minute Walk Test — 224; 247 meters

Primary: To Evaluate Over the Aggregate IMPROVE-HF Practice Sites the Relative Changes in 7 Performance Measures at 24 Months Compared With Baseline and Determine the Number of…

Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL

Primary: Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations — 84; 62; 42; 24 msec — p=0.8842

Primary: Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From…

Primary: Safety as Measured by the Percentage of Participants Free From System Related Complications Through 6 Months. — 277 Participants

Primary: Events Per Person-year — 84; 57 events/person-year — p=0.094

Primary: Number of Patients Free From Major Adverse Cardiac and Neurological Events (MACNE) at 6 Weeks. — 51 Participants